Vanguard Group Inc Arcutis Biotherapeutics, Inc. Transaction History

Vanguard Group Inc

  • $6.57 Trillion
  • Q4 2025

A detailed history of Vanguard Group Inc transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 7,253,936 shares of ARQT stock, worth $181 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,253,936
Previous 7,146,090 1.51%
Holding current value
$181 Million
Previous $135 Million 34.63%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 29, 2026
BUY
$19.64 - $25.31 $2.12 Million - $2.73 Million
107,846 Added 1.51%
7,253,936 $181 Million
Q3 2025

Nov 07, 2025
BUY
$13.39 - $18.85 $1.3 Million - $1.83 Million
96,991 Added 1.38%
7,146,090 $135 Million
Q2 2025

Aug 11, 2025
BUY
$12.59 - $16.6 $2.91 Million - $3.83 Million
231,021 Added 3.39%
7,049,099 $98.8 Million
Q1 2025

May 09, 2025
BUY
$11.4 - $17.29 $4.3 Million - $6.52 Million
377,363 Added 5.86%
6,818,078 $107 Million
Q4 2024

Feb 11, 2025
SELL
$8.31 - $14.99 $4.34 Million - $7.82 Million
-521,920 Reduced 7.5%
6,440,715 $89.7 Million
Q3 2024

Nov 13, 2024
BUY
$8.32 - $11.0 $6.81 Million - $9 Million
818,345 Added 13.32%
6,962,635 $64.8 Million
Q2 2024

Aug 13, 2024
BUY
$7.24 - $12.53 $7.08 Million - $12.3 Million
977,873 Added 18.93%
6,144,290 $57.1 Million
Q1 2024

May 10, 2024
BUY
$3.25 - $11.77 $877,188 - $3.18 Million
269,904 Added 5.51%
5,166,417 $51.2 Million
Q4 2023

Feb 14, 2024
BUY
$1.84 - $4.82 $3.71 Million - $9.72 Million
2,017,053 Added 70.05%
4,896,513 $15.8 Million
Q3 2023

Nov 14, 2023
BUY
$5.31 - $10.98 $1.22 Million - $2.52 Million
229,072 Added 8.64%
2,879,460 $15.3 Million
Q2 2023

Aug 14, 2023
BUY
$7.51 - $15.0 $512,610 - $1.02 Million
68,257 Added 2.64%
2,650,388 $25.3 Million
Q1 2023

May 15, 2023
BUY
$10.23 - $17.14 $518,855 - $869,323
50,719 Added 2.0%
2,582,131 $28.4 Million
Q4 2022

Feb 10, 2023
BUY
$13.96 - $20.4 $3.89 Million - $5.68 Million
278,473 Added 12.36%
2,531,412 $37.5 Million
Q3 2022

Nov 14, 2022
BUY
$17.85 - $26.95 $8.11 Million - $12.2 Million
454,276 Added 25.26%
2,252,939 $43.1 Million
Q2 2022

Aug 12, 2022
BUY
$16.33 - $22.2 $4.37 Million - $5.94 Million
267,565 Added 17.48%
1,798,663 $38.3 Million
Q1 2022

May 13, 2022
BUY
$14.38 - $22.79 $241,152 - $382,188
16,770 Added 1.11%
1,531,098 $29.5 Million
Q4 2021

Feb 14, 2022
BUY
$14.98 - $25.5 $331,372 - $564,085
22,121 Added 1.48%
1,514,328 $31.4 Million
Q3 2021

Nov 12, 2021
SELL
$19.28 - $27.1 $39,890 - $56,069
-2,069 Reduced 0.14%
1,492,207 $35.6 Million
Q2 2021

Aug 13, 2021
BUY
$24.42 - $34.75 $36.5 Million - $51.9 Million
1,494,276 New
1,494,276 $40.8 Million

Others Institutions Holding ARQT

# of Institutions
260
Shares Held
127M
Call Options Held
404K
Put Options Held
133K
View Full List

About Arcutis Biotherapeutics, Inc.

ARQT Quotes by TradingView
  • Ticker ARQT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,187,500
  • Market Cap $1.5B
  • Description
  • Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...
More about ARQT
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email